{
    "organizations": [],
    "uuid": "57879cd1d37e22d1e02c650f0542dc868058b2c9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-staidson-beijing-biopharmaceutical/brief-staidson-beijing-biopharmaceuticals-sees-fy-2017-net-profit-could-rise-up-to-5-pct-idUSL4N1P52U3",
    "ord_in_thread": 0,
    "title": "BRIEF-Staidson Beijing BioPharmaceuticals sees FY 2017 net profit could rise up to 5 pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Staidson Beijing BioPharmaceuticals Co Ltd\n* Says it sees FY 2017 net profit could rise by up to 5 percent, or to be 257.3 million yuan to 270.1 million yuan\n* Says the net profit of FY 2016 was 257.3 million yuan\n* Comments that increased income of polyethylene glycol electrolyte as main reason for the forecast\nSource text in Chinese: goo.gl/Rtxod1\nFurther company coverage: (Beijing Headline News)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-10T16:23:00.000+02:00",
    "crawled": "2018-01-11T12:37:53.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "staidson",
        "beijing",
        "biopharmaceuticals",
        "co",
        "ltd",
        "say",
        "see",
        "fy",
        "net",
        "profit",
        "could",
        "rise",
        "percent",
        "million",
        "yuan",
        "million",
        "yuan",
        "say",
        "net",
        "profit",
        "fy",
        "million",
        "yuan",
        "comment",
        "increased",
        "income",
        "polyethylene",
        "glycol",
        "electrolyte",
        "main",
        "reason",
        "forecast",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}